AU2019352354B2 - Prophylactic or therapeutic drug for benign tumor - Google Patents

Prophylactic or therapeutic drug for benign tumor Download PDF

Info

Publication number
AU2019352354B2
AU2019352354B2 AU2019352354A AU2019352354A AU2019352354B2 AU 2019352354 B2 AU2019352354 B2 AU 2019352354B2 AU 2019352354 A AU2019352354 A AU 2019352354A AU 2019352354 A AU2019352354 A AU 2019352354A AU 2019352354 B2 AU2019352354 B2 AU 2019352354B2
Authority
AU
Australia
Prior art keywords
peptide
seq
cells
item
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019352354A
Other languages
English (en)
Other versions
AU2019352354A1 (en
Inventor
Haruo Sugiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Institute of Cancer Immunology Inc
Original Assignee
International Institute of Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Institute of Cancer Immunology Inc filed Critical International Institute of Cancer Immunology Inc
Publication of AU2019352354A1 publication Critical patent/AU2019352354A1/en
Assigned to INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., Sumitomo Pharma Co., Ltd. reassignment INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. Amend patent request/document other than specification (104) Assignors: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., SUMITOMO DAINIPPON PHARMA CO., LTD.
Application granted granted Critical
Publication of AU2019352354B2 publication Critical patent/AU2019352354B2/en
Assigned to INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. reassignment INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. Request for Assignment Assignors: Sumitomo Pharma Co., Ltd., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A01K2217/077—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out heterozygous knock out animals displaying phenotype
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019352354A 2018-10-05 2019-10-04 Prophylactic or therapeutic drug for benign tumor Active AU2019352354B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018190461 2018-10-05
JP2018-190461 2018-10-05
PCT/JP2019/039383 WO2020071551A1 (ja) 2018-10-05 2019-10-04 良性腫瘍の予防または治療薬

Publications (2)

Publication Number Publication Date
AU2019352354A1 AU2019352354A1 (en) 2021-05-13
AU2019352354B2 true AU2019352354B2 (en) 2025-07-03

Family

ID=70054693

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019352354A Active AU2019352354B2 (en) 2018-10-05 2019-10-04 Prophylactic or therapeutic drug for benign tumor

Country Status (10)

Country Link
US (1) US12440546B2 (https=)
EP (1) EP3865146A4 (https=)
JP (1) JP7393752B2 (https=)
KR (1) KR102901715B1 (https=)
CN (1) CN113395976B (https=)
AU (1) AU2019352354B2 (https=)
CA (1) CA3115240A1 (https=)
MX (1) MX2021003938A (https=)
TW (1) TWI851607B (https=)
WO (1) WO2020071551A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116970059A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
TW202208395A (zh) * 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
EP4149953A4 (en) * 2020-05-12 2024-06-26 Lg Chem, Ltd. MULTIMER T CELL MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
CN120484057A (zh) * 2025-05-07 2025-08-15 宁夏医科大学总医院 一种治疗结直肠息肉的短肽及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523784A (ja) * 2014-08-04 2017-08-24 フレッド ハッチンソン キャンサー リサーチ センター Ｗｔ−１に特異的なｔ細胞免疫治療
US20180140691A1 (en) * 2015-05-20 2018-05-24 Sumitomo Dainippon Pharma Co., Ltd. Combination use of wt1 antigen peptide and immunomodulator

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP940432B1 (en) 1994-08-05 2003-10-31 Pliva Pharm & Chem Works Dna sequences encoding biosynthetic insulin precursors and process for preparation of insulin
CN1560078B (zh) * 1998-07-31 2011-06-22 株式会社国际癌症免疫研究所 基于癌抑制基因wt1的产物的癌抗原
ATE340560T1 (de) * 1999-05-24 2006-10-15 Introgen Therapeutics Inc Verfahren und zusammensetzungen für nichtvirale gentherapie zur behandlung von hyperproliferativen krankheiten
ES2298353T3 (es) 2001-03-22 2008-05-16 International Institute Of Cancer Immunology, Inc. Peptido wt1 modificado.
WO2003106682A1 (ja) 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
WO2004024175A1 (ja) * 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
ATE442378T1 (de) 2002-09-20 2009-09-15 Int Inst Cancer Immunology Inc Substituierte wt1-peptide
CN101098708A (zh) * 2004-11-10 2008-01-02 胡布雷希特实验室 通过抑制Notch途径激活治疗肠腺瘤和/或腺癌
ES2352855T3 (es) 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
ES2679127T3 (es) * 2007-12-05 2018-08-22 International Institute Of Cancer Immunology, Inc. Composición vacunal contra el cáncer
WO2012037551A2 (en) * 2010-09-17 2012-03-22 Irx Therapeutics, Inc. Primary cell-derived biologic and wt1 synthetic long peptide vaccine
JP6117515B2 (ja) 2011-11-01 2017-04-19 国立大学法人名古屋大学 髄膜腫治療用医薬組成物
WO2013096297A1 (en) * 2011-12-20 2013-06-27 North Carolina State University Methods to reduce polyposis and colorectal cancer
MY171854A (en) * 2013-03-29 2019-11-05 Sumitomo Dainippon Pharma Co Ltd Wt1 antigen peptide conjugate vaccine
MX392470B (es) 2014-12-11 2025-03-24 Int Inst Cancer Immunology Inc Composición farmacéutica que comprende un péptido wt1 para el tratamiento o prevención de una enfermedad angiogénica.
LT3377516T (lt) * 2015-11-20 2022-09-26 Memorial Sloan Kettering Cancer Center Kompozicija vėžiui gydyti
EP3604325A4 (en) * 2017-03-30 2021-01-13 Sumitomo Dainippon Pharma Co., Ltd. WT1 CANCER ANTIGEN PEPTIDE AND PEPTIDE CONJUGATE BODY WITH IT
JP6741049B2 (ja) 2018-08-07 2020-08-19 カシオ計算機株式会社 注文処理装置及びプログラム

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523784A (ja) * 2014-08-04 2017-08-24 フレッド ハッチンソン キャンサー リサーチ センター Ｗｔ−１に特異的なｔ細胞免疫治療
US20180140691A1 (en) * 2015-05-20 2018-05-24 Sumitomo Dainippon Pharma Co., Ltd. Combination use of wt1 antigen peptide and immunomodulator

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AMINI NIK S. ET AL.: "Upregulation of Wlms' tumor gene 1 (WT1) in desmoid tumors", INTERNATIONAL JOURNAL OF CANCER, vol. 114, no. 2, 2005, pages 202 - 208, XP055700055 *
NOMURA, MASAYA ET AL.: "A Case of Heterochronous Ascending Colon Carcinoid 7 Years after Curative Resection of Descending Colon Carcinoid", THE JAPANESE JOURNAL OF GASTROENTEROLOGICAL SURGERY, vol. 37, no. 2, 2004, pages 217 - 222 *

Also Published As

Publication number Publication date
KR102901715B1 (ko) 2025-12-18
MX2021003938A (es) 2021-08-11
US20220008528A1 (en) 2022-01-13
JP7393752B2 (ja) 2023-12-07
JPWO2020071551A1 (ja) 2021-09-24
US12440546B2 (en) 2025-10-14
KR20210073540A (ko) 2021-06-18
TW202027777A (zh) 2020-08-01
TWI851607B (zh) 2024-08-11
EP3865146A1 (en) 2021-08-18
WO2020071551A1 (ja) 2020-04-09
CA3115240A1 (en) 2020-04-09
EP3865146A4 (en) 2022-06-29
CN113395976B (zh) 2025-11-21
AU2019352354A1 (en) 2021-05-13
CN113395976A (zh) 2021-09-14
NZ774631A (en) 2024-03-22

Similar Documents

Publication Publication Date Title
EP2385117B1 (en) HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same
EP2228072B1 (en) Cancer vaccine composition
RU2481398C2 (ru) Hla-a*1101-ограниченный пептид wt1 и содержащая его фармацевтическая композиция
EP2186896B1 (en) Cancer antigen peptides derived from WT1
AU2019352354B2 (en) Prophylactic or therapeutic drug for benign tumor
HK40051038A (en) Prophylactic or therapeutic drug for benign tumor
EP2891663B1 (en) Psf1-derived peptides
HK1125968B (en) Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
HK1143552B (en) Cancer vaccine composition
HK1143552A (en) Cancer vaccine composition

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.

Free format text: FORMER NAME(S): SUMITOMO DAINIPPON PHARMA CO., LTD.; INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.

Owner name: SUMITOMO PHARMA CO., LTD.

Free format text: FORMER NAME(S): SUMITOMO DAINIPPON PHARMA CO., LTD.; INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.

PC1 Assignment before grant (sect. 113)

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.

Free format text: FORMER APPLICANT(S): SUMITOMO PHARMA CO., LTD.; INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.

FGA Letters patent sealed or granted (standard patent)